These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 15195634

  • 21. Thiazolidinediones and fluid retention.
    Kiryluk K, Isom R.
    Kidney Int; 2007 Sep; 72(6):762-8. PubMed ID: 17637710
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
    Hartung DM, Touchette DR, Bultemeier NC, Haxby DG.
    Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Actos and Avandia in type 2 diabetes. Where do they fit?
    Clark W.
    Diabetes Self Manag; 2007 Oct; 24(4):8, 11-3. PubMed ID: 17663078
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The rise and fall of rosiglitazone.
    Nissen SE.
    Eur Heart J; 2010 Apr; 31(7):773-6. PubMed ID: 20154334
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI.
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract] [Full Text] [Related]

  • 34. Thiazolidinediones.
    Mascitelli L, Pezzetta F.
    N Engl J Med; 2005 Jan 13; 352(2):205-7; author reply 205-7. PubMed ID: 15651125
    [No Abstract] [Full Text] [Related]

  • 35. Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.
    Wang F, Vergara C, Carabino J, Desilets A, Vasquez R.
    Am J Health Syst Pharm; 2004 Aug 01; 61(15):1604-8. PubMed ID: 15372837
    [No Abstract] [Full Text] [Related]

  • 36. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS.
    Am J Health Syst Pharm; 2007 Dec 01; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract] [Full Text] [Related]

  • 37. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC.
    Am Heart J; 2004 Oct 01; 148(4):551-8. PubMed ID: 15459582
    [Abstract] [Full Text] [Related]

  • 38. The painful truth.
    Nissen SE.
    Eur Heart J; 2010 May 01; 31(10):1284-5. PubMed ID: 20418344
    [No Abstract] [Full Text] [Related]

  • 39. The rise and fall of rosiglitazone: reply.
    Slaoui M.
    Eur Heart J; 2010 May 01; 31(10):1282-4. PubMed ID: 20499440
    [No Abstract] [Full Text] [Related]

  • 40. Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone.
    Clevidence DE, Juckett MB, Lucarelli MJ.
    WMJ; 2009 Dec 01; 108(9):462-5. PubMed ID: 20131689
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.